Gene expression is regulated by a number of interrelated posttranslational modifications of histones, including citrullination. For example, peptidylarginine deminase 4 (PAD4) converts peptidyl arginine to citrulline in histone H3 and can repress gene expression. However, regulation of gene expression through citrullination of non-histone proteins is less well defined. Herein, we identify a tumor suppressor protein, inhibitor of growth 4 (ING4), as a novel non-histone substrate of PAD4. ING4 is known to bind p53 via its nuclear localization signal (NLS) region and to enhance transcriptional activity of p53. We show that PAD4 preferentially citrullinates ING4 in the same NLS region and thereby disrupts the interaction between ING4 and p53. A citrulline-mimicking Arg-NLS-Gln ING4 mutant, which has all Arg residues in the NLS mutated to Gln, loses its affinity for p53, can no longer promote p53 acetylation, and results in repression of downstream p21 expression. In addition, we found that citrullination leads to increased susceptibility of ING4 to degradation, likely impacting p53-independent pathways as well. These findings elucidate an interaction between posttranslational citrullination, acetylation, and methylation and highlight an unusual mechanism whereby citrullination of a non-histone protein impacts gene regulation.Protein arginine deiminases (PADs 2 or PADIs) catalyze the posttranslational modification of peptidyl arginine and, more slowly, peptidyl monomethylarginine to form peptidyl citrulline. This citrullination reaction is a hydrolytic deimination that eliminates the positive charge of the arginine side chain, can lead to changes in inter-and intraprotein interactions, and can even cause localized protein unfolding (1, 2). The human PAD4 isoform is calcium-regulated, nuclear-targeted, and is of particular interest because of its role in gene regulation as a catalyst of histone modification and chromatin remodeling (3). PAD4 expression is up-regulated in a variety of human malignant cancers, and PAD4-specific inhibitors can kill a selection of cancerous cells lines including HL-60, MCF7, and HT-29 (4). Accordingly, PAD4 has been suggested as a possible target for anticancer therapeutics (5).Some PAD4-interacting non-histone proteins have also been identified, including the tumor suppressor p53 (6). PAD4 binds p53 and inhibits p53-regulated cell cycle arrest and apoptosis. Through this interaction, PAD4 gets recruited to gene promoters that are targeted by p53 and, in the case of p21, can downregulate expression. Reciprocally, p53 can regulate the expression of PAD4 through a p53-response element located in a PAD4 gene intron (7). These findings suggest one mechanism whereby PAD4 can promote cancerous growth through its interactions with p53, although other unidentified pathways may also contribute.PAD4 also acts through citrullination of non-histone proteins, such as p300 (8). The p300 protein, histone methyltransferase coactivator-associated arginine methyltransferase-1 (CARM1) and glucocorticoid rec...